ENTA

Enanta Pharmaceuticals, Inc.
CAPPED RATING

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals, Inc. (ENTA) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.7
EV / EBITDA -5.9
Rev Growth YoY -21.6%
Gross Margin N/M
Price Return 3M -16.9%
Price Return 12M 2.1%
Catalyst Signal 0.00
Market Cap $326.8M
TTM Revenue $65.3M
Price / Sales 5.0
ROE -70.1%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) D+ (1.6) B- (3.0) C+ (2.5) C+ (2.6) C+ (2.6)
2026-11-04 B- (3.0) D+ (1.6) B- (3.1) C (2.5) C+ (2.7) C+ (2.6)
2026-10-28 B- (3.0) D+ (1.5) B- (2.9) C+ (2.7) C+ (2.7) C+ (2.6)
2026-10-21 B- (3.0) D+ (1.5) B- (2.9) C (2.4) C+ (2.6) C (2.5)
2026-10-14 B- (3.0) D+ (1.5) B- (2.9) C (2.4) C+ (2.6) C+ (2.5)
Page 1 of 8
…